Version 1
: Received: 13 July 2023 / Approved: 13 July 2023 / Online: 14 July 2023 (13:24:12 CEST)
How to cite:
Asadollahzadeh, E.; Ebadi, Z.; Rezaeimanesh, N.; Naser Moghadasi, A. Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis. Preprints2023, 2023070990. https://doi.org/10.20944/preprints202307.0990.v1
Asadollahzadeh, E.; Ebadi, Z.; Rezaeimanesh, N.; Naser Moghadasi, A. Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis. Preprints 2023, 2023070990. https://doi.org/10.20944/preprints202307.0990.v1
Asadollahzadeh, E.; Ebadi, Z.; Rezaeimanesh, N.; Naser Moghadasi, A. Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis. Preprints2023, 2023070990. https://doi.org/10.20944/preprints202307.0990.v1
APA Style
Asadollahzadeh, E., Ebadi, Z., Rezaeimanesh, N., & Naser Moghadasi, A. (2023). Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis. Preprints. https://doi.org/10.20944/preprints202307.0990.v1
Chicago/Turabian Style
Asadollahzadeh, E., Nasim Rezaeimanesh and Abdorreza Naser Moghadasi. 2023 "Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis" Preprints. https://doi.org/10.20944/preprints202307.0990.v1
Abstract
Multiple sclerosis (MS) is a persistent inflammatory disease affecting the central nervous system. Bruton's tyrosine kinase (BTK) is an enzyme crucial in the communication process of B cells, which have a significant impact on the development of MS. Recently, BTK inhibitors have emerged as a promising treatment strategy for MS due to their ability to modulate the immune system. In this study, an extensive literature search was performed utilizing multiple databases, such as PubMed, Embase, and Scopus to examine the potential use of BTK inhibitors in managing cognitive disorders experienced by individuals with MS. We found that BTK inhibitors targeting microglia offer potential advantages for managing neurodegeneration associated with cognitive impairments in MS patients by slowing down degeneration processes effectively. Their ability to impact microglial function and penetrate the CNS positions them as promising candidates for improving cognitive function. This study suggests that BTK inhibitors provide new possibilities for managing inflammatory and neurodegenerative phases of MS through their effects on microglia activation pathways. Further research and clinical trials are necessary to fully explore their efficacy in treating MS while addressing barriers related to cognitive impairment.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
